

Pending Claims:

Claims 1-64 (canceled)

65. (original) A method of inhibiting a T-cell mediated immune response in a mammal, comprising exposing mammalian cells to DcR3 polypeptide or a chimeric molecule comprising DcR3 polypeptide.

66. (canceled)

67. (Previously presented) A method of treating or preventing an inflammatory disease or disorder comprising administering to an animal a therapeutically effective amount of a polypeptide selected from the group consisting of: (a) a polypeptide comprising amino acid residues 1 to 300 of SEQ ID NO:1; (b) a polypeptide comprising amino acid residues 24 to 300 of SEQ ID NO:1; (c) a polypeptide comprising amino acid residues 24 to 215 of SEQ ID NO:1; (d) a polypeptide comprising the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 209254; and (e) a polypeptide comprising the amino acid sequence of the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209254.

68. (Previously presented) The method of claim 67 wherein the animal is human.

69. (Previously presented) The method of claim 67 wherein the polypeptide is fused to a heterologous polypeptide.

70. (Previously presented) The method of claim 69 wherein the heterologous polypeptide is an immunoglobulin constant domain.

71. (Previously presented) The method of claim 67 wherein the inflammatory disease or disorder is inflammatory bowel disease.

72. (Previously presented) The method of claim 67 wherein the inflammatory disease or disorder is psoriasis.

73. (Previously presented) A method of treating or preventing inflammation comprising administering to an animal a therapeutically effective amount of a polypeptide selected from the group consisting of:

(a) a polypeptide comprising amino acid residues 1 to 300 of SEQ ID NO:1; (b) a polypeptide comprising amino acid residues 24 to 300 of SEQ ID NO:1; (c) a polypeptide comprising amino acid residues 24 to 215 of SEQ ID NO:1; (d) a polypeptide comprising the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 209254; and (f) a polypeptide comprising the amino acid sequence of the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209254.

74. (Previously presented) The method of claim 73 wherein the animal is human.

75. (Previously presented) The method of claim 73 wherein the polypeptide is fused to a heterologous polypeptide.

76. (Previously presented) The method of claim 75 wherein the heterologous polypeptide is an immunoglobulin constant domain.

77. (Previously presented) A method of treating or preventing an autoimmune disease or disorder comprising administering to an animal a therapeutically effective amount of a polypeptide selected from the group consisting of: (a) a polypeptide comprising amino acid residues 1 to 300 of SEQ ID NO:1; (b) a polypeptide comprising amino acid residues 24 to 300 of SEQ ID NO:1; (c) a polypeptide comprising amino acid residues 24 to 215 of SEQ ID NO:1; (d) a polypeptide comprising the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 209254; and (e) a polypeptide comprising the amino acid sequence of the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209254.

78. (Previously presented) The method of claim 77 wherein the animal is human.

79. (Previously presented) The method of claim 77 wherein the polypeptide is fused to a heterologous polypeptide.

80. (Previously presented) The method of claim 79 wherein the heterologous polypeptide is an immunoglobulin constant domain.

81. (Previously presented) The method of claim 77 wherein the autoimmune disease or disorder is systemic lupus erythematosus.

82. (Previously presented) The method of claim 77 wherein the autoimmune disease or disorder is arthritis.

83. (Previously presented) The method of claim 77 wherein the autoimmune disease or disorder is rheumatoid arthritis.

84. (Previously presented) The method of claim 77 wherein the autoimmune disease or disorder is multiple sclerosis.

85. (Previously presented) The method of claim 77 wherein the autoimmune disease or disorder is Crohn's disease.

86. (Previously presented) A method of treating or preventing graft vs. host disease (GVHD) comprising administering to an animal a therapeutically effective amount of a polypeptide selected from the group consisting of: (a) a polypeptide comprising amino acid residues 1 to 300 of SEQ ID NO:1; (b) a polypeptide comprising amino acid residues 24 to 300 of SEQ ID NO:1; (c) a polypeptide comprising amino acid residues 24 to 215 of SEQ ID NO:1; (d) a polypeptide comprising the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 209254; and (e) a polypeptide comprising the amino acid sequence of the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209254.

87. (Previously presented) The method of claim 86 wherein the animal is human.

88. (Previously presented) The method of claim 86 wherein the polypeptide is fused to a heterologous polypeptide.

89. (Previously presented) The method of claim 88 wherein the heterologous polypeptide is an immunoglobulin constant domain.

90. (Previously presented) A method of treating or preventing allergy or asthma comprising administering to an animal a therapeutically effective amount of a polypeptide selected from the group consisting of: (a) a polypeptide comprising amino acid residues 1 to 300 of SEQ ID NO:1; (b) a polypeptide comprising amino acid residues 24 to 300 of SEQ ID NO:1; (c) a polypeptide comprising amino acid residues 24 to 215 of SEQ ID NO:1; (d) a polypeptide comprising the amino acid sequence

of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 209254; and
(e) a polypeptide comprising the amino acid sequence of the mature form of the polypeptide encoded
by the cDNA contained in ATCC Deposit Number 209254.

91. (Previously presented) The method of claim 90 wherein the animal is human.

92. (Previously presented) The method of claim 90 wherein the polypeptide is fused to a heterologous
polypeptide.

93. (Previously presented) The method of claim 92 wherein the heterologous polypeptide is an
immunoglobulin constant domain.